Immuneering Corp financial data

Symbol
IMRX on Nasdaq
Location
245 Main Street, Second Floor, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 595 % -53.8%
Debt-to-equity 24.8 % +101%
Return On Equity -146 % -122%
Return On Assets -117 % -99.4%
Operating Margin -12.3M % -127560%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 38M USD -84.1%
Weighted Average Number of Shares Outstanding, Basic 36M shares +21.4%
Weighted Average Number of Shares Outstanding, Diluted 36M shares +21.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Cost of Revenue 0 USD -100%
Research and Development Expense 48M USD +9.63%
General and Administrative Expense 16M USD -3.7%
Operating Income (Loss) -64.1M USD -5.97%
Net Income (Loss) Attributable to Parent -62.1M USD -10.8%
Earnings Per Share, Basic -1 USD/shares 0%
Earnings Per Share, Diluted -1 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26.4M USD -55.9%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 27.7M USD -56.5%
Property, Plant and Equipment, Net 964K USD -25.3%
Operating Lease, Right-of-Use Asset 3.5M USD -8.59%
Goodwill 6.69M USD 0%
Other Assets, Noncurrent 842K USD -31.5%
Assets 40.1M USD -48%
Accounts Payable, Current 2.4M USD -8.66%
Accrued Liabilities, Current 4.51M USD +20.2%
Liabilities, Current 7.49M USD +10.4%
Operating Lease, Liability, Noncurrent 3.63M USD -9.17%
Liabilities 11.1M USD +3.14%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -254M USD -32.4%
Stockholders' Equity Attributable to Parent 28.9M USD -56.4%
Liabilities and Equity 40.1M USD -48%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.1M USD +9.11%
Net Cash Provided by (Used in) Financing Activities 13.8M USD +1309%
Net Cash Provided by (Used in) Investing Activities 21.4M USD +12.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -279K USD -104%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26.4M USD -55.9%
Deferred Tax Assets, Valuation Allowance 59M USD +36.3%
Deferred Tax Assets, Gross 59.3M USD +35.9%
Operating Lease, Liability 4M USD -7.22%
Depreciation 90.2K USD +17.9%
Payments to Acquire Property, Plant, and Equipment 8.95K USD -76.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -62.1M USD -10.8%
Lessee, Operating Lease, Liability, to be Paid 5.6M USD -11.5%
Property, Plant and Equipment, Gross 2.22M USD +0.75%
Operating Lease, Liability, Current 367K USD +17.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 785K USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 762K USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.6M USD -20.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 808K USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 25.3M USD +32.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.14M USD +62.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 833K USD +3%
Operating Lease, Payments 184K USD -4.7%
Additional Paid in Capital 283M USD +9.6%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 29.3K USD 0%
Depreciation, Depletion and Amortization 345K USD -1.13%
Deferred Tax Assets, Net of Valuation Allowance 344K USD -11.6%
Share-based Payment Arrangement, Expense 6.58M USD +26.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%